Today, the Human Rights Campaign Foundation released new data outlining the outsized economic impact…Read more
HRC responded to the Trump-Pence administration’s announcement opposing the Equality Act, crucially…Read more
Tonight, the Human Rights Campaign and artist Robin Bell projected the CDC’s banned words onto the …Read more
Today, HRC responded to the decision by a U.S. Federal Judge to block enforcement of the Trump-Pence Administration’s unconstitutional ban on military service by transgender troops.
“Today’s preliminary injunction is an important step in the ongoing efforts to protect transgender service members from the dangerous and discriminatory policies of Donald Trump and Mike Pence,” said Sarah Warbelow, HRC’s Legal Director. “Donald Trump’s erratic tweets and half-baked orders disrespect the bravery of the countless transgender people who have fought, and in many cases died, for their country. The immediate harm to our national defense and to the thousands of transgender people serving and wishing to serve their country must be stopped — and we are grateful that a federal judge has blocked this administration from discharging any qualified individuals because of their gender identity while these cases continue to make their way through the courts.”Read more
Today, HRC and the National Center for Lesbian Rights (NCLR), a national legal organization committed to …Read more
Today, HRC Foundation and Faith in America, which works to advance LGBTQ equality in faith communiti…Read more
HRC hailed the adoption of resolutions by the American Medical Association (AMA) opposing discriminatory …Read more
Today, HRC Foundation responded to the important decision by the Food and Drug Administration (FDA) to approve a generic version of Truvada, the potentially lifesaving antiretroviral medication used for HIV treatment and prevention. Before today’s decision, Truvada was the only medication FDA-approved for PrEP in the United States.
“While the timeline is uncertain for when a generic drug will be available to consumers, today’s decision by the FDA is a much-needed breakthrough in our ongoing efforts to expand HIV prevention options, especially for those most vulnerable to HIV and AIDS” said Mary Beth Maxwell, HRC Senior Vice President for Programs, Research and Training. “Despite growing use of PrEP nationally, the drug remains out-of-reach for many in the communities hardest hit by the epidemic, including young gay and bisexual men and transgender women of color. We implore Gilead to continue their critical payment assistance programs and urge other companies to provide similar financial relief.”
HRC is committed to working with our allies, partners, members, and supporters to end the dual epidemics of HIV and HIV-related stigma. In 2014, HRC endorsed the use of PrEP, recognizing that when taken as prescribed by a healthcare provider, PrEP has been shown to be safe and highly effective at reducing one’s chances of contracting HIV. PrEP is not right for all individuals, and any medical decision should be made in concert with a knowledgeable healthcare provider.
To learn more about PrEP, visit http://www.hrc.org/resources/is-prep-right-for-me.Read more
Today HRC Foundation announced that U.S. Senator Al Franken (D-MN), whose career has been marked by his c…Read more
In the wake of the deaths of at least seven transgender people in just the first two months of this year,…Read more